Showing 1 - 20 results of 120 for search '"Фармакоэкономика"', query time: 0.05s Refine Results
  1. 1
    The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups

    The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups by E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan

    Published 2020-11-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Mathematical modeling and analysis of export trends for certain pharmaceutical groups

    Mathematical modeling and analysis of export trends for certain pharmaceutical groups by А. R. Shaikhislamova, N. А. Gasratova

    Published 2024-08-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Is it worthwhile rethinking the positive experience of the last 50 years of using chondroitin sulfates against atherosclerosis?

    Is it worthwhile rethinking the positive experience of the last 50 years of using chondroitin sulfates against atherosclerosis? by A. M. Lila, I. Yu. Torshin, O. A. Gromova

    Published 2020-08-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    LEGAL REGULATION OF STATE MANAGEMENT OF MEDICAL SCIENCE

    LEGAL REGULATION OF STATE MANAGEMENT OF MEDICAL SCIENCE by L. S. Melnikova, O. Yu. Rebrova, V. V. Omelyanovskiy

    Published 2015-12-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS

    REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS by Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev

    Published 2015-09-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis

    Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis by N. Yu. Nikolenko, D. А. Kudlay, N. P. Doktorova

    Published 2021-07-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Biophysical modeling indicates a high affinity of ethyl esters of omega-3 polyunsaturated fatty acids to the enzymes of the pro-inflammatory arachidonic acid cascade

    Biophysical modeling indicates a high affinity of ethyl esters of omega-3 polyunsaturated fatty acids to the enzymes of the pro-inflammatory arachidonic acid cascade by I. Yu. Torshin, O. A. Gromova

    Published 2022-07-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation

    Long-term analysis of сanagliflozin budget impact in adult patients with type 2 diabetes mellitus and diabetic nephropathy in the Russian Federation by N. A. Avxentyev, Yu. V. Makarova

    Published 2022-10-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT

    PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT by N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova

    Published 2016-04-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION

    ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION by M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Economic burden of chronic viral hepatitis C

    Economic burden of chronic viral hepatitis C by R. A. Yakhina, I. A. Lakman, D. A. Valishin, R. Kh. Bakhitova

    Published 2022-01-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders

    Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders by O. A. Gromova, I. Yu. Torshin, A. N. Gromov, O. V. Tikhonova

    Published 2024-02-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY

    ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY by D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky

    Published 2015-05-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly

    Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly by I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin

    Published 2025-05-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM

    CLINICAL AND ECONOMIC EVALUATION OF IVABRADINE USE IN STABLE ANGINA IN TERMS OF REPUBLIC OF BELARUS HEALTH CARE SYSTEM by I. N. Kozhanova, I. S. Romanova, L. N. Gavrilenko, A. V. Patseev, M. M. Sachek

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Pharmacoeconomic study of active psoriatic arthritis treatment

    Pharmacoeconomic study of active psoriatic arthritis treatment by A. V. Rudakova, Т. V. Korotaeva

    Published 2025-02-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Using indirect comparisons in pharmacoeconomic examination

    Using indirect comparisons in pharmacoeconomic examination by Yu. E. Balykina, A. S. Kolbin

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Systematic analysis of molecules regulating nitric oxide (NO) metabolism and vascular endothelium condition

    Systematic analysis of molecules regulating nitric oxide (NO) metabolism and vascular endothelium condition by I. Yu. Torshin, A. G. Chuchalin, O. A. Gromova

    Published 2025-05-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019

    Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019 by D. V. Fedyaev, V. V. Omelyanovskiy, M. L. Lazareva, Yu. V. Seryapina, Yu. A. Ledovskikh

    Published 2019-10-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    RATIONALE FOR THE SYSTEM OF INDICATORS, INTENDED FOR THE EVALUATION OF INVESTMENT EFFECTIVENESS IN THE FINANCING OF INVESTMENT PROJECTS IMPLEMENTED USING THE FUNDS OF THE POPULATION

    RATIONALE FOR THE SYSTEM OF INDICATORS, INTENDED FOR THE EVALUATION OF INVESTMENT EFFECTIVENESS IN THE FINANCING OF INVESTMENT PROJECTS IMPLEMENTED USING THE FUNDS OF THE POPULATIO... by E. V. Litvinenko

    Published 2015-03-01
    “…Фармакоэкономика…”
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: